Shifting beauty pressures, celebrity influence, and weight-loss culture are reshaping what it means to feel at home in a changing body.
Public conversations about bodies have rarely been rational, but the current Ozempic Moment is unusually disorienting. A surge in weight-loss drugs, the return of visibly extreme thinness on red carpets, and a booming aesthetic-medicine market have collided to create a climate where nearly every physical choice — gaining weight, losing weight, aging, intervening — comes with a side effect of unrelenting scrutiny. The resulting discourse punishes contradictions: too thin, too large, too sculpted, too natural.
Kate Winslet has become one of the few high-profile figures directly acknowledging this confusion. In a new interview with the Sunday Times, the 50-year-old actress called the widespread use of injectable weight-loss drugs “devastating,” adding, “If a person’s self-esteem is so bound up in how they look, it’s frightening.” She described a landscape where some embrace their natural selves, while others “do everything they can to not be themselves.” What unsettles her most is the risk people are willing to take without fully understanding the consequences. “And do they know what they are putting in [their bodies]? The disregard for one’s health is terrifying. It bothers me now more than ever. It is f—— chaos out there.”
Her comments come as prescriptions for GLP-1 medications like Ozempic and Wegovy have surged dramatically; data from Fair Health shows the percentage of obese or overweight adults who didn’t have diabetes prescribed GLP-1s increased 1,961 percent between 2019 and 2024, with demand still climbing as new pill formulations enter the market. Industry analysts estimate that global sales of obesity and weight-loss drugs could exceed $100 billion within a decade, reshaping wellness and pharmaceutical economics in real time.
At the same time, Winslet’s critique touches a rarely discussed nuance: the blurring line between wellness and aesthetics. Research from the American Society of Plastic Surgeons reports that nonsurgical cosmetic procedures grew nearly 20 percent year-over-year, with injectables leading the category. Winslet expressed sadness that younger women feel compelled to erase signs of living. “My favorite thing is when your hands get old,” she said. “That’s life, in your hands.”
Winslet has been outspoken about body image since her early career. After Titanic, she faced merciless commentary about her body. The attention, she said, felt invasive and destabilizing. The criticism echoed a familiar message: attractiveness was synonymous with being smaller, tighter, lighter — a message she now sees repeating in new forms, amplified by pharmaceutical speed and social-media reach.
The celebrity diet industrial complex
Jameela Jamil’s recent response to Serena Williams’ promotion of a GLP-1 medication tapped into the same unease, though from a slightly different angle. Jamil emphasized that her concern was not about Williams’ decision to use GLPs. Instead, she highlighted the risks of normalizing pharmaceutical interventions as routine beauty tools.
“Serena Williams is selling GLP-1s,” she wrote in an Instagram post, before warning that celebrities often receive levels of medical oversight unavailable to most consumers. She listed an array of potential side effects from the drugs: “paralysis of the gastric system, pancreatitis, cancer, hair loss, osteoporosis, severe malnutrition, muscle mass loss, depression (there have been reports of suicide), thyroid issues, blindness, and they can really wreak havoc on your metabolism.”
Her argument aligns with emerging medical research. Several recent studies, including recent findings of clinically significant loss of lean muscle mass among some GLP-1 users, a side effect that can carry long-term metabolic implications. And while the drugs can be medically transformative for people with diabetes or obesity, off-label cosmetic use raises new questions about safety, access, and informed consent.
Williams’ husband, Alexis Ohanian, is an investor in Ro, the company whose product she promoted. For Jamil, this highlighted the broader ecosystem of endorsements, profit incentives, and aspirational marketing. “Another reason we should take every celebrity endorsement with a pinch of salt,” she wrote.
Still, the controversy also revealed a cultural paradox: public appetite for transparency coexists with public punishment for it. When a celebrity discloses using medication, they may be accused of reckless influence. When they stay silent, they may be accused of misleading fans. No answer pleases everyone.
The thinness aesthetic returns
What many observers find more troubling is how these pharmaceutical trends mirror a visual shift already unfolding across entertainment and social media. HuffPost writer Rebecca Morrison traced this pattern through the cultural ubiquity of Ariane Grande, Cynthia Erivo, and other high-profile figures, noting the re-emergence of extremely thin silhouettes reminiscent of earlier decades. “Extreme thinness is back, and it’s being packaged as aspiration,” she wrote.
Morrison’s piece underscores the generational stakes. As she explains, her adolescence in the 1980s was shaped by low-fat dieting fads, calorie-counting obsessions, and an almost total absence of public discourse around mental health or disordered eating. The pressures led her into decades of bulimia — “a secret life I carried for the next 30 years,” she wrote. She sees the current wave of weight-loss culture as both familiar and newly alarming: the aesthetic is the same, but the tools are far more potent and accessible.
Her reporting echoes data from the Centers for Disease Control and Prevention, which has documented a concerning rise in eating-disorder symptoms among adolescents since the pandemic. Treatment centers across the United States have reported record-high admissions, with some facilities noting patient increases of up to 30 percent.
For Morrison, the danger goes beyond individual celebrities’ choices and to the economic, algorithmic, and pharmaceutical influences that reward shrinking, smoothing, optimizing. “We fought for size diversity,” she wrote, “for the radical idea that you can be beautiful, strong and worthy without disappearing.” Yet she argues that the new wave of “pharmaceutical shrinking” risks resetting the clock on progress, recasting thinness as synonymous with discipline and wellness.
The contradictions keep piling up. A woman with visible injectables is chastised for vanity; one without them is told she looks “tired.” Someone who gains weight is accused of letting herself go; someone who loses weight is accused of promoting unrealistic ideals. Even Gordon Ramsay found himself briefly entangled in the discourse after social-media users joked that a low-calorie tasting menu at his restaurant amounted to an “Ozempic menu,” sparking commentary about whether diet culture had moved from celebrity bodies into culinary marketing.
Its become an incoherent argument about health and beauty shaped by a fragmented value system: control is good, but not too much; youth is admirable, but not if achieved artificially; self-acceptance is celebrated, but only within certain aesthetic limits.
Bodies shift for countless reasons, and people will approach medication, aging, and appearance in ways that make sense for them. Turning those choices into moral judgments — on thinness, weight, cosmetic treatments, or aging — rarely helps anyone understand what is actually at play.
“I actually admire transparency,” Jamil wrote. “I have an issue with privileged celebrities pushing drugs with dangerous side effects to their followers, when so many lack appropriate healthcare,” she added. For Winslet, it touches on something even deeper. “Some of the most beautiful women I know are over 70,” she said. “And what upsets me is that young women have no concept of what being beautiful actually is.”
Related on Ethos:
